These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2295792)

  • 1. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol.
    Katre NV
    J Immunol; 1990 Jan; 144(1):209-13. PubMed ID: 2295792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
    Yang Z; Wang J; Lu Q; Xu J; Kobayashi Y; Takakura T; Takimoto A; Yoshioka T; Lian C; Chen C; Zhang D; Zhang Y; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Sep; 64(18):6673-8. PubMed ID: 15374983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.
    Chen SA; Sawchuk RJ; Brundage RC; Horvath C; Mendenhall HV; Gunther RA; Braeckman RA
    J Pharmacol Exp Ther; 2000 Apr; 293(1):248-59. PubMed ID: 10734176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models.
    Zimmerman RJ; Aukerman SL; Katre NV; Winkelhake JL; Young JD
    Cancer Res; 1989 Dec; 49(23):6521-8. PubMed ID: 2819708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A highly enhanced thrombopoietic activity by monomethoxy polyethylene glycol-modified recombinant human interleukin-6.
    Inoue H; Kadoya T; Kabaya K; Tachibana K; Nishi N; Sato M; Ohsawa M; Mikayama T; Mori KJ
    J Lab Clin Med; 1994 Oct; 124(4):529-36. PubMed ID: 7930877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site.
    Goodson RJ; Katre NV
    Biotechnology (N Y); 1990 Apr; 8(4):343-6. PubMed ID: 1366535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation.
    Sun X; Yang Z; Li S; Tan Y; Zhang N; Wang X; Yagi S; Yoshioka T; Takimoto A; Mitsushima K; Suginaka A; Frenkel EP; Hoffman RM
    Cancer Res; 2003 Dec; 63(23):8377-83. PubMed ID: 14678999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2.
    Bernsen MR; Dullens HF; Den Otter W; Heintz PM
    J Interferon Cytokine Res; 1995 Jul; 15(7):641-5. PubMed ID: 7553236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical modification of recombinant human keratinocyte growth factor 2 with polyethylene glycol improves biostability and reduces animal immunogenicity.
    Huang Z; Ni C; Chu Y; Wang S; Yang S; Wu X; Wang X; Li X; Feng W; Lin S
    J Biotechnol; 2009 Jul; 142(3-4):242-9. PubMed ID: 19477206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vivo antitumor effects of polyethylene glycol--modified recombinant human interleukin-2 on mouse uterine cervical carcinoma].
    Wang L; Wu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 1996 Jul; 18(4):253-5. PubMed ID: 9387313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of polyethylene glycol modification on the circulatory stability and immunogenicity of recombinant human butyrylcholinesterase.
    Chilukuri N; Sun W; Naik RS; Parikh K; Tang L; Doctor BP; Saxena A
    Chem Biol Interact; 2008 Sep; 175(1-3):255-60. PubMed ID: 18603232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next generation OP-bioscavengers: a circulatory long-lived 4-PEG hypolysine mutant of F338A-HuAChE with optimal pharmacokinetics and pseudo-catalytic characteristics.
    Kronman C; Cohen O; Mazor O; Ordentlich A; Raveh L; Velan B; Shafferman A
    Chem Biol Interact; 2010 Sep; 187(1-3):253-8. PubMed ID: 20005217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate.
    Yang Z; Sun X; Li S; Tan Y; Wang X; Zhang N; Yagi S; Takakura T; Kobayashi Y; Takimoto A; Yoshioka T; Suginaka A; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Aug; 64(16):5775-8. PubMed ID: 15313919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein carboxyl amidation increases the potential extent of protein polyethylene glycol conjugation.
    Li S; Yang Z; Sun X; Tan Y; Yagi S; Hoffman RM
    Anal Biochem; 2004 Jul; 330(2):264-71. PubMed ID: 15203332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S; Naruo K; Shiho O; Tsukamoto K
    Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
    Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
    J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.
    Leong SR; DeForge L; Presta L; Gonzalez T; Fan A; Reichert M; Chuntharapai A; Kim KJ; Tumas DB; Lee WP; Gribling P; Snedecor B; Chen H; Hsei V; Schoenhoff M; Hale V; Deveney J; Koumenis I; Shahrokh Z; McKay P; Galan W; Wagner B; Narindray D; Hébert C; Zapata G
    Cytokine; 2001 Nov; 16(3):106-19. PubMed ID: 11741351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.